{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:38:00Z","timestamp":1750307880957,"version":"3.41.0"},"reference-count":139,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323527255"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/b978-0-323-52725-5.00004-6","type":"book-chapter","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T19:39:03Z","timestamp":1494617943000},"page":"51-66","source":"Crossref","is-referenced-by-count":1,"title":["Lipid-Based Nanocarriers in\u00a0Cancer Therapy"],"prefix":"10.1016","author":[{"given":"Marilene","family":"Estanqueiro","sequence":"first","affiliation":[]},{"given":"Maria H.","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Sousa Lobo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.17.1.593","article-title":"Mechanisms of phagocytosis in macrophages","volume":"17","author":"Aderem","year":"1999","journal-title":"Annu. Rev. Immunol."},{"issue":"Suppl. 4","key":"10.1016\/B978-0-323-52725-5.00004-6_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00003495-199700544-00004","article-title":"Liposomes. Opportunities in drug delivery","volume":"54","author":"Allen","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0020","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-04-2517","article-title":"Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates","volume":"11","author":"Allen","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0690","unstructured":"Azaya therapeutics. 2014. Azaya therapeutics - products pipeline. Available from: http:\/\/www.azayatherapeutics.com\/pipeline\/ati-1123"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0025","unstructured":"American Cancer Society Chemotherapy principles. Available from: http:\/\/www.cancer.org\/treatment\/treatmentsandsideeffects\/treatmenttypes\/chemotherapy\/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment\/chemotherapy-principles-what-is-chemo"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0030","unstructured":"National Cancer Institute at the National Institutes of Health, Defining cancer. Available from: http:\/\/www.cancer.gov\/cancertopics\/cancerlibrary\/what-is-cancer"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.biopha.2014.01.004","article-title":"Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung","volume":"68","author":"Athawale","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae - the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(01)01938-9","article-title":"Is transdermal drug delivery research still important today?","volume":"6","author":"Barry","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0045","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1021\/nn103362n","article-title":"Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release","volume":"5","author":"Basel","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1242\/jcs.115.4.849","article-title":"Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target","volume":"115","author":"Beningo","year":"2002","journal-title":"J. Cell. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0055","first-page":"463","article-title":"Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma","volume":"7","author":"Bogner","year":"1994","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0060","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","article-title":"Hyperfractionated Irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer","volume":"338","author":"Brizel","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100\u00a0nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0610","unstructured":"Celsion Corporation. 2011. THERMODOX\u00ae. Available from: http:\/\/celsion.com\/docs\/technology_thermodox."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0695","unstructured":"Celator Pharmaceuticals. 2014a. CPX-1 and Colorectal Cancer. Available from: http:\/\/www.celatorpharma.com\/new\/products_CPX1.html."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0700","unstructured":"Celator Pharmaceuticals. 2014b. CPX-351 and Acute Myeloid Leukemia. Available from: http:\/\/www.celatorpharma.com\/new\/products_cpx351.html."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v13.i3-4.30","article-title":"Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery","volume":"13","author":"Cevc","year":"1996","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0005-2736(92)90154-E","article-title":"Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force","volume":"1104","author":"Cevc","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1053-4296(98)80041-6","article-title":"Modification of tumor blood flow: current status and future directions","volume":"8","author":"Chaplin","year":"1998","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0085","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.biomaterials.2011.04.053","article-title":"Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides","volume":"32","author":"Cheng","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0090","series-title":"Cancer: principles and practice of oncology","article-title":"Miscellaneous Chemotherapeutic Agents","author":"Cheson","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0095","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0100","series-title":"Cancer: principles and practice of oncology","article-title":"Antimetabolites","author":"Chu","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0615","unstructured":"Clinical Trials Search. 2014. Safety Study of Infusion of SGT-53 to Treat Solid Tumors. Available from: http:\/\/www.clinicaltrialssearch.org\/safety-study-of-infusion-of-sgt-53-to-treat-solid-tumors-nct00470613.html."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0105","series-title":"Cancer: principles and practice of oncology","article-title":"Antitumor Alkylating Agents","author":"Colvin","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0620","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bjc.1996.362","article-title":"Current perspectives on camptothecins in cancer treatment","volume":"74","author":"Dancey","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0115","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.2042-7158.1997.tb06025.x","article-title":"Enhanced anticancer therapy mediated by specialized liposomes","volume":"49","author":"Dass","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11095-008-9697-x","article-title":"Intravascular delivery of particulate systems: does geometry really matter?","volume":"26","author":"Decuzzi","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0125","doi-asserted-by":"crossref","first-page":"21495","DOI":"10.1073\/pnas.0907127106","article-title":"Red blood cell-mimicking synthetic biomaterial particles","volume":"106","author":"Doshi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0130","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.talanta.2005.08.044","article-title":"Liposomes in analyses","volume":"68","author":"Edwards","year":"2006","journal-title":"Talanta"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0625","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5955(02)00277-0","article-title":"D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics","volume":"165","author":"Ekborn","year":"2002","journal-title":"Hear. Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/(SICI)1521-2254(199905\/06)1:3<210::AID-JGM30>3.0.CO;2-U","article-title":"Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI)","volume":"1","author":"Erbacher","year":"1999","journal-title":"J. Gene Med."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ics.12109","article-title":"Characterization, sensorial evaluation and moisturizing efficacy of nanolipidgel formulations","volume":"36","author":"Estanqueiro","year":"2014","journal-title":"Int. J. Cosmet. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2004.02.022","article-title":"Effect of \u03b2-sitosterol on the characteristics of vesicular gels containing chlorhexidine","volume":"278","author":"Farkas","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0155","unstructured":"Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., Bray, F., 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. Available from: http:\/\/globocan.iarc.fr"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0160","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0360-3016(96)00389-6","article-title":"Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks","volume":"36","author":"Gaber","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0630","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nnano.2007.70","article-title":"Shape effects of filaments versus spherical particles in flow and drug delivery","volume":"2","author":"Geng","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0170","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0005-2736(01)00398-4","article-title":"Cargo delivery kinetics of cell-penetrating peptides","volume":"1515","author":"H\u00e4llbrink","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0180","first-page":"423","article-title":"Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues","volume":"75","author":"Herrmann","year":"1985","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ddtec.2005.05.003","article-title":"Vesicles as a tool for transdermal and dermal delivery","volume":"2","author":"Honeywell-Nguyen","year":"2005","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0190","first-page":"3645","article-title":"Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?","volume":"5","author":"Hong","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0195","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.bjc.6601341","article-title":"Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner","volume":"89","author":"Hosokawa","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/713817583","article-title":"Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization","volume":"19","author":"Jenning","year":"2002","journal-title":"J. Microencapsul."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0205","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.biomaterials.2013.01.039","article-title":"Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs","volume":"34","author":"Joo","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0210","series-title":"Cancer: principles and practice of oncology","article-title":"Molecular Biology of Cancer: The Cell Cycle","author":"Kastan","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(02)00628-2","article-title":"Preparation and pharmacokinetics of pirarubicin loaded dehydration-rehydration vesicles","volume":"252","author":"Kawano","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0220","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0225","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1039\/B611022N","article-title":"Cell-assisted assembly of colloidal crystallites","volume":"3","author":"Kodali","year":"2007","journal-title":"Soft Matter"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0235","first-page":"6950","article-title":"Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release","volume":"60","author":"Kong","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0240","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.carbpol.2013.01.091","article-title":"Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy","volume":"94","author":"Kong","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2012.08.009","article-title":"Immunoconjugates and long circulating systems: origins, current state of the art and future directions","volume":"65","author":"Koshkaryev","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0250","first-page":"208","article-title":"Nonionic surfactant vesicular systems for effective drug delivery\u2014an overview","volume":"1","author":"Kumar","year":"2011","journal-title":"Acta Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jcsb.2012.1020","article-title":"Preparation, characterization and applications of liposomes: state of the art","volume":"1","author":"Laouini","year":"2012","journal-title":"J. Colloid Sci. Biotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0167-7799(98)01220-7","article-title":"Novel applications of liposomes","volume":"16","author":"Lasic","year":"1998","journal-title":"Trends Biotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0169-409X(98)00095-7","article-title":"Liposomes for scintigraphic detection of infection and inflammation","volume":"37","author":"Laverman","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0378-5173(99)00428-7","article-title":"Investigation on the viscoelastic properties of lipid based colloidal drug carriers","volume":"196","author":"Lippacher","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0280","unstructured":"Lucks, J.S., M\u00fcller, R.H., 1991. Medication vesicles made of solid lipid particles (solid lipid Nanospheres SLN). EP0000605497."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0285","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1521-3773(20010504)40:9<1707::AID-ANIE17070>3.0.CO;2-F","article-title":"pH-responsive polymer microspheres: rapid release of encapsulated material within the range of intracellular pH","volume":"40","author":"Lynn","year":"2001","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0290","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nano.2012.10.003","article-title":"Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells","volume":"9","author":"Madan","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0295","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1211\/0022357991776813","article-title":"Skin delivery of eestradiol from deformable and traditional liposomes: mechanistic studies","volume":"51","author":"Maghraby","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0300","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1211\/0022357011776450","article-title":"Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro","volume":"53","author":"Maghraby","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","article-title":"Niosomes from 80s to present: the state of the art","volume":"205","author":"Marianecci","year":"2014","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0310","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ejpb.2013.08.011","article-title":"Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration","volume":"85","author":"Martins","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(99)00042-3","article-title":"Possibility of active targeting to tumor tissues with liposomes","volume":"40","author":"Maruyama","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0635","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0640","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.colsurfb.2013.03.037","article-title":"Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells","volume":"110","author":"Miao","year":"2013","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0330","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/187152006778699095","article-title":"New generation of liposomal drugs for cancer","volume":"6","author":"Minko","year":"2006","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0335","first-page":"4681","article-title":"Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids","volume":"39","author":"Modolell","year":"1979","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0645","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11912-001-0016-5","article-title":"Liposomal encapsulated anthracyclines: new therapeutic horizons","volume":"3","author":"Muggia","year":"2001","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0345","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0350","series-title":"Submicron Emulsions In Drug Targeting And Delivery","article-title":"Solid Lipid Nanoparticles (SLN\u00ae) for controlled drug delivery","author":"Muller","year":"1998"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0355","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art","volume":"50","author":"Muller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"Suppl. 1","key":"10.1016\/B978-0-323-52725-5.00004-6_bib0360","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Muller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1557\/S0883769400053240","article-title":"Materials engineering of lipid bilayers for drug carrier performance","volume":"24","author":"Needham","year":"1999","journal-title":"MRS Bull."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0370","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0169-409X(01)00233-2","article-title":"The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors","volume":"53","author":"Needham","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0650","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jnci\/83.16.1164","article-title":"Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer","volume":"83","author":"Negoro","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0375","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2007.11.037","article-title":"Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer","volume":"353","author":"Paolino","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0380","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejpb.2012.02.008","article-title":"Paclitaxel-loaded ethosomes\u00ae: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses","volume":"81","author":"Paolino","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0168-3659(01)00315-7","article-title":"Tumor targeting using anti-Her2 immunoliposomes","volume":"74","author":"Park","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0395","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/B978-0-323-52725-5.00004-6_bib0400","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0405","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jconrel.2013.05.020","article-title":"Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches","volume":"170","author":"Pradhan","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0410","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijpharm.2008.01.045","article-title":"Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation","volume":"357","author":"Puglia","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0415","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/156720105774370294","article-title":"The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations","volume":"2","author":"Ramsay","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0420","series-title":"Cancer: principles and practice of oncology","article-title":"Antimicrotubule Agents","author":"Rowinsky","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0425","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0360-3016(00)01476-0","article-title":"Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis","volume":"49","author":"Ruiter","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0430","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archinte.1970.00310120093014","article-title":"Physiology and physiopathology of the reticuloendothelial system","volume":"126","author":"Saba","year":"1970","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0435","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-03-0376","article-title":"Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0440","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","article-title":"Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents","volume":"10","author":"Schell","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0445","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2009.03.007","article-title":"Ultrasound triggered release of cisplatin from liposomes in murine tumors","volume":"137","author":"Schroeder","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0450","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(97)00135-X","article-title":"Liposomes in drug delivery: progress and limitations","volume":"154","author":"Sharma","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2009.02.002","article-title":"Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage","volume":"136","author":"Shmeeda","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0460","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.colsurfb.2012.01.014","article-title":"Solid lipid nanoparticles (SLN)\u2014based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies","volume":"93","author":"Silva","year":"2012","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0465","series-title":"Nanoparticles for pharmaceutical applications","article-title":"Liposomes for Drug Delivery","author":"Simard","year":"2007"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0470","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/17425240903071029","article-title":"Vesicular carriers for dermal drug delivery","volume":"6","author":"Sinico","year":"2009","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0655","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The Current Status of Camptothecin Analogues as Antitumor Agents","volume":"85","author":"Slichenmyer","year":"1993","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0660","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol. J."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0475","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/02652040500435295","article-title":"Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization","volume":"23","author":"Souto","year":"2006","journal-title":"J. Microencapsul."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","article-title":"Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery","volume":"278","author":"Souto","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0485","series-title":"Cancer: principles and practice of oncology","article-title":"Topoisomerase Interactive Agents","author":"Stewart","year":"2001"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0490","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0665","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/wnan.1257","article-title":"What nanomedicine in the clinic right now really forms nanoparticles? Wiley Interdiscip","volume":"6","author":"Svenson","year":"2014","journal-title":"Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0495","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.75.9.4194","article-title":"Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation","volume":"75","author":"Szoka","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0500","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1006\/bbrc.1998.9460","article-title":"Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking","volume":"251","author":"Tachibana","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0505","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0510","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.colsurfb.2012.09.019","article-title":"Doxorubicin loaded magneto-niosomes for targeted drug delivery","volume":"102","author":"Tavano","year":"2013","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0515","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2007.01.015","article-title":"Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10)\u2014development, physicochemical characterization and in vitro release studies","volume":"67","author":"Teeranachaideekul","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0520","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0525","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.addr.2006.09.009","article-title":"Multifunctional nanocarriers","volume":"58","author":"Torchilin","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0530","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0535","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1073\/pnas.151247498","article-title":"TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors","volume":"98","author":"Torchilin","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0540","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2003.10.006","article-title":"Deformable liposomes for dermal administration of methotrexate","volume":"270","author":"Trotta","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0001-8686(95)00242-I","article-title":"Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry","volume":"58","author":"Uchegbu","year":"1995","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0550","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0031-6865(95)00010-7","article-title":"Preparation and characterization of liposomes as therapeutic delivery systems: a review","volume":"70","author":"Vemuri","year":"1995","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0555","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5173(97)00425-0","article-title":"From mixed micelles to liposomes: critical steps during detergent removal by membrane dialysis","volume":"162","author":"Wacker","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0670","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0675","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clml.2013.03.015","article-title":"Phase I\/II trial of nanomolecular liposomal annamycin in adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"13","author":"Wetzler","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0680","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalton Trans."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0560","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.addr.2007.04.008","article-title":"Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles","volume":"59","author":"Wong","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0565","first-page":"3765","article-title":"Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue","volume":"53","author":"Wu","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0570","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.canlet.2012.07.002","article-title":"Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer","volume":"334","author":"Yang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0685","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0575","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.364652","article-title":"Design of liposomes for enhanced local release of drugs by hyperthermia","volume":"202","author":"Yatvin","year":"1978","journal-title":"Science"},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0580","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2174\/138161210791920496","article-title":"Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects","volume":"16","author":"Yoo","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0585","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/marc.200900592","article-title":"Endocytosis and intracellular distribution of PLGA particles in endothelial cells: effect of particle geometry","volume":"31","author":"Yoo","year":"2010","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0590","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.addr.2011.05.004","article-title":"Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery","volume":"63","author":"Yoo","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00004-6_bib0595","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1053-4296(98)80042-8","article-title":"Transvascular drug delivery in solid tumors","volume":"8","author":"Yuan","year":"1998","journal-title":"Semin. Radiat. Oncol."}],"container-title":["Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323527255000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323527255000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T14:35:23Z","timestamp":1750257323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323527255000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780323527255"],"references-count":139,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-52725-5.00004-6","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}